Brief: Newron Pharmaceuticals: XADAGO to be introduced in Portugal
10/04/2017 06:38
April 10 (Reuters) - Newron Pharmaceuticals S.p.A. NWRN.S :
* ZAMBON S.p.A., and partner Newron Pharmaceuticals S.p.A.,
introduce XADAGO (Safinamide) for patients in the middle to late
stage of Parkinson's disease in Portugal
Source text for Eikon: urn:newsml:reuters.com:*:nEQ3zHkrk
Further company coverage: NWRN.S
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study